Could a cannabis compound help ADHD? new trial tests CBG

NCT ID NCT06115603

Recruiting now Symptom relief Sponsor: University of Arkansas, Fayetteville Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether a single dose of cannabigerol (CBG), a non-psychoactive cannabis compound, can improve attention and reduce hyperactivity in adults with ADHD. 76 participants will receive either 80mg of CBG or a placebo, then complete computer and paper tasks measuring focus, memory, and decision-making. The study aims to see if CBG offers a new way to ease ADHD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabigerol (CBG)
What this could lead to: If it works, this could point toward a new, non-stimulant option for easing ADHD symptoms like inattention and impulsivity.
What could go wrong: This is a small, early-phase trial testing only a single dose. It may show no benefit over placebo, and long-term safety and effectiveness are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT HYPERACTIVITY DISORDER

Contacts and locations

Locations

University of Arkansas
RECRUITING

Fayetteville, Arkansas, 72703, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.